Novel topical formulation of CY-002 works safe against cutaneous warts, study finds
Netherlands: The topical formulation of CY-002 was safe and manageable for daily treatment in patients with cutaneous warts, as per new findings from a randomized, placebo-controlled, first-in-human study, published in The Journal of the European Academy of Dermatology and Venereology.
CY-002 is a topical formulation of a new 27-amino acid alpha-helical tumour membrane-targeting peptide designed to deliver HPV-oriented, immune-targeted therapy in afflicted individuals. Treatments for cutaneous warts have traditionally focused on the destruction of epithelium rather than the targeting of HPV-infected keratinocytes. As a result, Lisa Pagan and colleagues carried out this trial to investigate the tolerability, safety, and effectiveness of topical CY-002 in people with cutaneous warts.
Potential participants were 18 years or older, in good health, and had 1, 3 mm cutaneous warts on their hands. A washout of wart-removing agents was necessary for 30-60 days prior to treatment with the topical formulation. Following the washout, participants made weekly visits to the clinical research facility for 28 days of at-home therapy, and were followed up on at 6- and 12-week intervals. Once daily, one droplet of 15–30 mg CY-002 1 percent or placebo cream was applied, followed by overnight occlusion, and treatment adherence, including safety and effectiveness data, was tracked using a mobile e-diary application.
The key findings of this study were as follows:
1. A total of 55 individuals were included in the trial, with 52 completing therapy and 49 completing follow-up.
2. Baseline and illness features were similar in all patients, while patients on placebo were more treatment-naive than those on CY-002, at 67.9% and 33.3%, respectively.
3. In both groups, the mean home treatment compliance was 27 doses (96.4%) of the 28 scheduled CY-002 doses.
4. Only two patients experienced moderate application site discomfort, and adverse events were comparable across groups.
5. Following CY-002 therapy, investigators noticed that 2 patients (7.7%) obtained full clearance and 4 (15.4%) had clearance of 1 of treated lesions, whereas full clearance was seen in 1 (3.8%) patient and 3 (11.5%) patients had clearance of 1 of the treated lesions.
In conclusion, in this trial, there was a substantial placebo response, and the gap between CY-002 and placebo did not approach statistical significance. Thinking about multiple medication delivery techniques might help in the creation of CY-002 for cutaneous warts.
Reference:
Pagan, L., Yfanti, C., Rijneveld, R., Todd, M., Jongste, P., Feijen, J., Klaassen, E., Bouwes Bavinck, J., Struijk, L., de Koning, M., Prestegarden, L., and Rissmann, R. (2022), Results of a randomized, placebo-controlled, first-in-human trial of topical CY-002 in patients with cutaneous warts. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.18291
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.